Skip to Content
Resources

Life with GLP-1s

Sponsored White Paper

It’s Time to Reframe Obesity

Presented By

Omada Health

Document Info

Published on Apr 9, 2024

Download and read the full Resource.

Resource Details

Disclaimer

This white paper represents the views of the author, not America’s Health Insurance Plans (AHIP). The publication, distribution or posting of this white paper by AHIP does not constitute a guaranty of any product or service by AHIP.

Overview

In the U.S., obesity rates have been steadily increasing since the 1980s, including a sharp increase in adult obesity starting around 2010, despite much attention and research. In 2023, chronic diseases, including diabetes and hypertension, were among the leading drivers of our nation’s $4.1 trillion in annual health care costs.

When it comes to weight loss maintenance and long-term GLP-1 use, not all patients want to or need to de-prescribe, but many also will for a variety of reasons. For GLP-1 results to scale effectively, reframing the discourse around obesity is critical. Obesity is a complex chronic disease, as classified by the AMA, and it requires longterm––even lifelong––treatment that includes lifestyle interventions to sustain healthy weight loss during and long after GLP-1 use.